Navigation Links
S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now?
Date:2/8/2010

ge of preventative care and disease management.

S&P Equity Research believes the health insurance industry will face the brunt of any scaled back bill as insurance companies remain vulnerable to government intervention and are an easy target of any populist revolt.  One of the most likely and popular proposed reforms among both parties is the elimination of preexisting condition clauses in health insurance plans.  In response, we would expect the managed care organizations (MCOs) to move clients with preexisting conditions into medical management programs whereby the MCOs require certain regimens of care lest patients face financial penalties.  S&P Equity Research would not be surprised to see the government incent the MCOs with tax breaks or subsidies for such programs, so that insuring people with preexisting conditions does not become a money-losing proposition for the MCOs.  Even with these incentives, assuming Medicaid and/or Medicare Advantage enrollment grows faster than commercial enrollment; the MCOs are likely to see increasing margin pressure in the form of rising medical loss ratios.  Moreover, any expansion of Medicaid eligibility and continued Medicare Advantage reimbursement rate pressures should exacerbate this margin pressure.  In this environment, S&P Equity Research believes the pure-play Medicare Advantage providers and pure-play Medicaid players could benefit as they have experience controlling costs by transitioning members into more restrictive provider networks and through more active management of care.  Over time, S&P Equity Research expects all MCOs to increasingly adopt similar tactics.

The loss of the Democratic supermajority in the Senate may lead to upward earnings revisions for companies that could have been hurt by some of the health care reform proposals floated on Capital Hill.  We think many companies' 2010 earnings estimates incorporated potential c
'/>"/>

SOURCE Standard & Poor's
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology news :

1. Molecular Biometrics Closes $12.5 Million Series B Equity Funding
2. Equity concerns raised by congestion pricing can be addressed to make approach viable
3. Markets of biodiversity and equity in trade: An illusion?
4. SyntheMed Completes $2.8 Million Equity Financing
5. The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare
6. Research reveals link between beer and bone health
7. NIFA awards funding for animal health and production research
8. Leaders from the National Academies gather to discuss engineering innovations in health care
9. Play yourself healthy
10. Nutrition services, prevention important in nutrition care for special health needs
11. National Jewish Health researchers discover how virulent bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... Vermillion, Inc. (NASDAQ: VRML ), a ... health, announced the signing of a cooperative research and development ... Materiel Command (USAMRMC). The agreement kicks off ... Treatment Algorithm for Adnexal Masses in Women," and follows ...
... is pleased to announce it has received a grant ... Advanced Life Sciences Training Program. The grant will ... July 2013 for all five classes of participants in ... 2008. The Fellows Program is a high-level life science ...
... KISS 1 is a metastasis-suppressor gene which helps to ... ovarian cancers to name a few. But new ... Dentistry shows that kisspeptins peptide products of KISS1, actually ... grade and metastatic potential. The research is published ...
Cached Biology News:U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 2U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 3U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 4Keystone Symposia announces grant from Alfred P. Sloan Foundation 2
(Date:8/4/2015)... LOS ANGELES , Aug. 4, 2015   ... announced the recent acquisition of LifeLine Cryogenics, an east ... the New York tristate area. ... tissues, and all prepaid contracts will be honored. ... of cryogenics services, offering storage of sperm, eggs, embryos, ...
(Date:8/3/2015)... , Aug. 3, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental ... at the 35 th Annual Canaccord|Genuity Growth Conference ... "Pete" Petit, Chairman and CEO, William C. Taylor ...
(Date:8/3/2015)... , August 3, 2015 ... the commercialization of its Bio-electrical Signal Therapy device ("BST ... treatment of hard to heal chronic wounds, today announced ... with Chemipal, an Israeli distributor specializing in medical devices, ... Chemipal is a 70 years old, sales, ...
(Date:7/31/2015)... In today,s fast changing healthcare environment, ... positive health outcomes, improve profitability and enhance their ... in their communities. At ThoughtSpot 2015, Good ... announced a new set of innovative capabilities that ... help independent pharmacies endure the industry,s most pressing ...
Breaking Biology Technology:FamilyCord Announces Acquisition of LifeLine Cryogenics 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... Osteotech, Inc. (Nasdaq: OSTE ), a leader ... today that the Company,s second quarter ended June 30, 2010 ... Monday, August 9, 2010 .  The management team of Osteotech ... 9, 2010 , at 9:00 a.m. (EDT) to discuss ...
... Mass. , Aug. 4 New England ... Michael Smith Genome Sciences Center has selected New England ... sequencing library construction reagents. NEBNext DNA Sample Prep Reagent ... and validated for sample preparation for next generation sequencing, ...
... Elusys Therapeutics, Inc. (Elusys), a privately-held ... second contract year of funding valued at $40.6 million ... and treatment of anthrax infection following a biowarfare attack. This ... received under this contract and is part of a potential ...
Cached Biology Technology:Osteotech Announces Second Quarter 2010 Financial Results Release and Conference Call 2Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 2Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 3Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax 2Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax 3
Formula variant: With the macro- and micronutrients as described by Lloyd and McCown (1981). Preparation Quantity Equivalency: Formulated to contain 2.3 grams of powder per liter of medium. Physical ...
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... whose sequence corresponds to residues 1-18 from rat rab 3D. ... - A - S - A - S - E - ... - D - A - A - D - Q - ... control experiments with the polyclonal antibody that reacts with this product ...
... or individual RNA sequences from high throughput synthesis ... RNAs from LC Sciences. These products provide a ... of DESIGNED sequences delivered in a microtube as ... a single verified RNA sequence. This is a ...
Biology Products: